4D Molecular Therapeutics enrolls first patients in Phase 3 4SIGHT trial of 4D-150 for diabetic macular edema
Bitget2026/09/28 12:06- 4D Molecular Therapeutics enrolled the first patients in 4SIGHT, a global Phase 3 trial of 4D-150 in treatment-naïve diabetic macular edema.
- Updated two-year SPECTRA results were presented, supporting durable vision and anatomical improvements with reduced need for frequent injections.
- The program advances 4D-150 into a second large retinal market, extending its late-stage pipeline beyond wet AMD.
- Regulators have discussed a potential filing strategy that relies on this single DME Phase 3 study alongside prior DME and wet AMD data.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Federal Reserve Eyes $1.8 Trillion in “Shadow Credit”: Dallas and New York Fed Launch First Private Credit Survey
The Dallas and New York Federal Reserves have launched an investigation into private credit lending standards, covering an industry worth 1.8 trillions USD, with a minimum threshold of 50 millions USD. The results will be released in the first quarter of 2027.
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Crypto prices
More
